-
公开(公告)号：US20220372149A1
公开(公告)日：2022-11-24
申请号：US17662518
申请日：2022-05-09
申请人： AGENUS INC. , LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. , MEMORIAL SLOAN-KETTERING CANCER CENTER
发明人： Marc VAN DIJK , Cornelia Anne MUNDT , Gerd RITTER , Jedd David WOLCHOK , Taha MERGHOUB , Roberta ZAPPASODI , Rikke Baek HOLMGAARD , David SCHAER , David Adam SAVITSKY , Nicholas Stuart WILSON
IPC分类号： C07K16/28 , A61P35/00 , A61K45/06 , A61K39/395
摘要： The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
-
公开(公告)号：US11485780B2
公开(公告)日：2022-11-01
申请号：US16913067
申请日：2020-06-26
IPC分类号： C07K16/22 , A61K47/68 , A61P35/00 , A61K39/395 , A61P35/04 , C07K16/30 , G01N33/574 , A61K45/06 , A61K39/00
摘要： Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 3 (TGF-β3) are provided, particularly recognizing human and mouse TGF-β3, particularly antibodies and fragments that do not recognize or bind TGF-β1 or TGF-β2. Particular antibodies are provided which specifically recognize and neutralize TGF-β3. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β3, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-β3 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody MTGF-β3-9, MTGF-β3-12, MTGF-β3-16, MTGF-β3-17 and MTGF-β3-19, whose sequences are provided herein.
-
公开(公告)号：US20220267781A1
公开(公告)日：2022-08-25
申请号：US17630068
申请日：2020-07-24
发明人： Zandra Walton , Zachary Stine , Yaoyu Gong , Chi Van Dang
IPC分类号： C12N15/62 , A61K35/17 , C07K14/47 , C07K14/705 , C12N5/0783 , C12N9/12 , C12N9/88
摘要： This disclosure provides methods for enhancing antitumor cytotoxicity of immune cells by introducing to the immune cells a genetic modification that comprises overexpression of RHEB or a functional fragment thereof, overexpression of LAMP 1-RHEB or a functional fragment thereof, overexpression of CA9 or a functional fragment thereof, overexpression of NHE1 or a functional fragment thereof, or combination thereof.
-
公开(公告)号：US20220227872A1
公开(公告)日：2022-07-21
申请号：US17613823
申请日：2020-05-29
申请人： Ludwig Institute for Cancer Research Ltd , Centre Hospitalier Universitaire Vaudois , Université de Lausanne
发明人： Steven M. Dunn , Julie K. Fierle , George Coukos
IPC分类号： C07K16/28 , C07K14/705 , C07K14/725 , A61P35/00
摘要： Provided herein are antibodies and antigen-binding portions thereof that bind to tumor endothelial marker 1 (TEM1), as well as methods of using the disclosed antibodies and antigen-binding portions thereof, including methods of treating cancer, reducing tumor growth, reducing tumor metastasis, and/or reducing tumor-associated fibrosis in a subject in need thereof.
-
公开(公告)号：US20220213543A1
公开(公告)日：2022-07-07
申请号：US17688424
申请日：2022-03-07
发明人： Chunxiao Song , Yibin Liu
IPC分类号： C12Q1/6869 , C12P17/16 , C12Q1/6844 , C12Q1/6874 , C12Q1/6876
摘要： This disclosure provides methods for bisulfite-free identification in a nucleic acid sequence of the locations of 5-methylcytosine, 5-hydroxymethylcytosine, 5-carboxylcytosine and 5-formylcytosine.
-
公开(公告)号：US20220177961A1
公开(公告)日：2022-06-09
申请号：US17504058
申请日：2021-10-18
发明人： Bing Ren , Siddarth Selvaraj , Jesse Dixon , Anthony Schmitt
IPC分类号： C12Q1/6874 , C12Q1/6869
摘要： The present invention relates to methods for haplotype determination and, in particular, haplotype determination at the whole genome level as well as targeted haplotype determination.
-
公开(公告)号：US20220098316A1
公开(公告)日：2022-03-31
申请号：US17446706
申请日：2021-09-01
申请人： AGENUS INC. , Ludwig Institute for Cancer Research Ltd. , Memorial Sloan-Kettering Cancer Center
发明人： Marc VAN DIJK , Ekaterina V. Breous-Nystrom , Volker Seibert , Gerd Ritter , David Schaer , Daniel Hirschhorn-Cymerman , Taha Merghoub , Hao Tang , David A. Savitsky , Jeremy Waight , Nicholas S. Wilson
IPC分类号： C07K16/28 , A61K39/395 , A61K45/06 , G01N33/68
摘要： The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.
-
公开(公告)号：US20210403545A1
公开(公告)日：2021-12-30
申请号：US17174859
申请日：2021-02-12
IPC分类号： C07K16/22 , A61K39/395
摘要： Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-β1) are provided, particularly recognizing human and mouse TGF-β1 and not recognizing or binding TGF-β2 or TGF-β3. Particular antibodies are provided which specifically recognize and neutralize TGF-β1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-β1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.
-
公开(公告)号：US20210205451A1
公开(公告)日：2021-07-08
申请号：US17121229
申请日：2020-12-14
申请人： Agenus Inc. , Ludwig Institute for Cancer Research Ltd , Memorial Sloan Kettering Cancer Center
发明人： Marc van Dijk , Cornelia Anne Mundt , Gerd Ritter , David Schaer , Jedd David Wolchok , Taha Merghoub , Nicholas Stuart Wilson , David Adam Savitsky , Mark Arthur Findeis , Dennis John Underwood , Jean-Marie Cuillerot , Igor Proscurshim , Olga Shebanova
IPC分类号： A61K39/395 , C07K16/28 , A61P11/00 , A61P35/04
摘要： The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
-
公开(公告)号：US20210113615A1
公开(公告)日：2021-04-22
申请号：US17046760
申请日：2019-04-12
发明人： George COUKOS , Melita IRVING , Bruno CORREIA , Pablo GAINZA-CIRAUQUI , Greta Maria Paola GIORDANO ATTIANESE
IPC分类号： A61K35/17 , C07K14/725 , C07K14/47
摘要： The invention relates to heterodimeric inactivatable chimeric antigen receptors (CARs) and their use for treatment.
-
-
-
-
-
-
-
-
-
搜索结果
137 条记录 (耗时 0.038 秒)
